Adhera Therapeutics, Inc.
Adhera Therapeutics, Inc. (ATRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
ATRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAdhera Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2003 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | -$0.00B | -100.00% |
| 2019-12-31 | $0.00B | +$0.00B | +230.77% |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | -$0.00B | -100.00% |
| 2015-12-31 | $0.00B | +$0.00B | +36.00% |
| 2014-12-31 | $0.00B | -$0.00B | -76.36% |
| 2013-12-31 | $0.00B | -$0.00B | -49.85% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Adhera Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Adhera Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Adhera Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ATRX revenue · 4 questionsATRX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Adhera Therapeutics, Inc. SEC filings · GAAP · Adhera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026